PDCD1 and neoplasm: Novel alternative approaches to target the PD-1/PD-L1 axis include the genetic modification of CAR-T cells to release a PD-1- or PD-L1-blocking scFv in the tumor (92, 93), to express PD-1 dominant negative receptors (86), or chimeric switch receptors (94).